0JW9 Stock Overview
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
MEI Pharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.75 |
52 Week High | US$7.86 |
52 Week Low | US$3.53 |
Beta | 0.65 |
1 Month Change | -15.84% |
3 Month Change | -41.34% |
1 Year Change | -23.25% |
3 Year Change | -94.39% |
5 Year Change | -93.97% |
Change since IPO | -91.51% |
Recent News & Updates
Recent updates
Shareholder Returns
0JW9 | GB Biotechs | GB Market | |
---|---|---|---|
7D | 6.2% | 2.4% | 2.3% |
1Y | -23.3% | -26.2% | 4.9% |
Return vs Industry: 0JW9 exceeded the UK Biotechs industry which returned -26.2% over the past year.
Return vs Market: 0JW9 underperformed the UK Market which returned 4.9% over the past year.
Price Volatility
0JW9 volatility | |
---|---|
0JW9 Average Weekly Movement | 9.4% |
Biotechs Industry Average Movement | 7.9% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: 0JW9's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0JW9's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 46 | David Urso | https://www.meipharma.com |
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer.
MEI Pharma, Inc. Fundamentals Summary
0JW9 fundamental statistics | |
---|---|
Market cap | US$25.52m |
Earnings (TTM) | US$19.84m |
Revenue (TTM) | US$72.65m |
1.3x
P/E Ratio0.4x
P/S RatioIs 0JW9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0JW9 income statement (TTM) | |
---|---|
Revenue | US$72.65m |
Cost of Revenue | -US$25.96m |
Gross Profit | US$98.61m |
Other Expenses | US$78.76m |
Earnings | US$19.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 2.98 |
Gross Margin | 135.73% |
Net Profit Margin | 27.32% |
Debt/Equity Ratio | 0% |
How did 0JW9 perform over the long term?
See historical performance and comparison